MedPath
HSA Approval

GLIOTENZIDE 20 TABLET

SIN12641P

GLIOTENZIDE 20 TABLET

GLIOTENZIDE 20 TABLET

January 14, 2005

ZYFAS PHARMA PTE LTD

ZYFAS PHARMA PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantZYFAS PHARMA PTE LTD
Licence HolderZYFAS PHARMA PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

C09BA02

enalapril and diuretics

Manufacturer Information

ZYFAS PHARMA PTE. LTD.

LABORATORIOS BAGO SA

Active Ingredients

ENALAPRIL MALEATE USP

20 mg

Enalapril

HYDROCHLOROTHIAZIDE USP

12.5 mg

Hydrochlorothiazide

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

GLIOTENZIDE 20 TABLET - HSA Approval | MedPath